Breaking the Debilitating Cycle: Pathophysiology, Assessment, and Multimodal Intervention of Secondary Debilitation After Hip Fracture in Older Adults-A Narrative Review.

Orthop Surg · 2026 · PMC13402652 · PMID 42503710

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

When administered as a single 30 mg/kg intravenous dose in patients with muscle‐related diseases, bimagrumab increased muscle mass at 8 weeks compared to controls, and showed a trend toward improvements in strength and function over the ensuing 24 weeks [ 155 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.